Cardinal Health reported its first quarter fiscal year 2025 results, exceeding earnings expectations and raising its fiscal year 2025 outlook. The company announced an adjusted earnings per share (EPS) of $1.88, surpassing the estimate of $1.62, with revenues of $52.28 billion, exceeding the anticipated $50.89 billion. Cardinal Health expects its fiscal year adjusted EPS to range between $7.75 and $7.90, and anticipates adjusted EBITDA for 2025 to be between $1.175 billion and $1.225 billion. The strong performance was attributed to increased demand for specialty medicines and branded drugs, leading to a nearly 7% rise in the company's stock price following the announcement.